Atlas Trials

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

Clinical trial NCT04780516 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04780516
Sponsor
AbbVie
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Psoriasis
Start date
2021-04-26
Primary completion
2024-01-02
Enrollment
141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.